CD38 and ovarian cancer: In both CRLM and OVC the percentage of CD38+/HLA-DR+ CD8+ T cells is increased five-fold and four-fold in TIL compared to PBL in ovarian cancer and CRC patients, respectively (Figure 5D-E).